Redsense Medical’s Chairman of the Board has passed away

Redsense Medical has received the sad news that the Chairman of the Board, Patrik Byhmer, has passed away.

Patrik Byhmer was the founder of the company and Chairman of the Board since August 2022 when he resigned as CEO. Patrik was instrumental in the development of the company and in establishing a disruptive and lifesaving technology for the dialysis market. The Board of Directors will appoint a Chairman of the Board among its current members until a new Chairman of the Board has been elected by the Annual General Meeting.

Pontus Nobréus, CEO of Redsense Medical comments: "Patrik will always be remembered as a warm, visionary and entrepreneurial leader with a strong sense of business acumen to bring new innovative products to the market”.

Our thoughts and heartfelt condolences are extended to Patriks's family and loved ones during this difficult period.

This information is information that Redsense Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out below, on December 23, 2023.

Contact information

For more information, please contact: 
Pontus Nobréus, CEO
Telephone: +46 72-171 1264
E-mail: pontus.nobreus (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.